|
TNBC, NSCLC, renal cell carcinoma
|
NCT02071862
|
1
|
2014
|
CB-839 (Telaglenastat)
|
–
|
|
CRC
|
NCT03263429
|
1/2
|
2017
|
CB-839
|
Panitumumab and irinotecan
|
|
AML
|
NCT03047993
|
1/2
|
2017
|
CB-839
|
Azacitidine
|
|
Hematological tumors
|
NCT02071888
|
1
|
2014
|
CB-839
|
–
|
|
Clear cell renal cell carcinoma, melanoma, NSCLC
|
NCT02771626
|
1/2
|
2016
|
CB-839
|
Nivolumab
|
|
NSCLC, CRC
|
NCT03965845
|
1/2
|
2019
|
CB-839
|
Palbociclib
|
|
Clear cell renal cell carcinoma, TNBC
|
NCT03875313
|
1/2
|
2019
|
CB-839
|
Talazoparib
|
|
NSCLC
|
NCT04265534
|
2
|
2020
|
CB-839
|
Pembrolizumab
|
|
TBNC
|
NCT03057600
|
2
|
2017
|
CB-839
|
Paclitaxel-carboplatin
|
|
Metastatic prostate cancer
|
NCT04824937
|
2
|
2021
|
CB-839
|
–
|
|
AML, ALL
|
NCT02071927
|
1
|
2018
|
CB-839
|
Azacitidine
|
|
Ovarian cancer
|
NCT03944902
|
1
|
2019
|
CB-839
|
Niraparib
|
|
Advanced renal cell carcinoma, metastatic renal cell carcinoma
|
NCT03428217
|
2
|
2018
|
CB-839
|
Cabozantinib
|
|
Malignant peripheral nerve sheath tumors
|
NCT03872427
|
2
|
2019
|
Telaglenastat hydrochloride
|
–
|
|
Leptomeningeal neoplasm, metastatic lung non-small cell carcinoma, metastatic malignant neoplasm in the brain
|
NCT04250545
|
1
|
2020
|
Telaglenastat hydrochloride
|
–
|
|
Plasma cell myeloma
|
NCT03798678
|
1
|
2019
|
Telaglenastat hydrochloride
|
Carfilzomib dexamethasone
|
|
Astrocytoma
|
NCT03528642
|
1
|
2019
|
Telaglenastat hydrochloride
|
Temozolomide
|
|
NSCLC
|
NCT03831932
|
1
|
2019
|
Telaglenastat hydrochloride
|
Osimertinib
|
